Summary of Federal Project Grant Award

Thrive Genetics, Inc. received a $305,358 Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279), effective June 1, 2026 through May 31, 2027. This Small Business Technology Transfer (STTR) Phase I award supports the development of an interactive, web-based personalized feedback program designed to identify individuals at risk for substance use disorders (SUDs) and deliver tailored prevention interventions. The program represents a collaboration between Thrive Genetics, Inc. and Dr. Danielle Dick, Director of the Rutgers Addiction Research Center, leveraging over 20 years of National Institutes of Health-funded addiction research to create a commercially viable product that delivers personalized risk estimates based on validated risk prediction science, followed by evidence-based recommendations and resources to mitigate SUD risk.

The Phase I effort focuses on feasibility assessment and commercial potential by building the interactive personalized feedback platform, consisting of two primary components: delivery of individualized risk estimates and provision of tailored preventive resources. The initiative addresses a significant market opportunity, as approximately 80% of individuals surveyed indicated willingness to receive personalized SUD risk information, and preliminary research suggests personalized risk feedback is more effective than standard prevention programs. Research will be conducted in Pennsylvania with performance metrics centered on demonstrating technical feasibility and commercial viability for subsequent Phase II development and public-scale deployment.